New year abuzz for MXC: Clinches exclusive cosmetics deal
Published 22-JAN-2018 13:09 P.M.
|
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MGC Pharmaceuticals today revealed that its European subsidiary, MGC Derma, has penned a strategic distribution agreement with renowned online cosmetics store, Cult Beauty.
Available to consumers worldwide, the deal will see 15 of MGC Derma’s cosmetics products sold on the Cult Beauty site, as well as its Derma Plus skincare range.
Cult Beauty will run a six-month exclusive sales campaign on these products. MGC Derma’s cosmetics will officially be launched by Cult Beauty on February 1.
Revenues from the deal in 2018 will be dependent on product sales and the six-month campaign.
Cult Beauty is a UK-based online beauty store that specialises in selling cutting-edge and hard-to-find beauty products to consumers around the world. Cultbeauty.com is an expertly curated experience that distils the global beauty industry down to its brightest – from the latest scientific discoveries to hundred-year-old remedies.
It’s worth noting here that this is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.
MXC’s MGC Derma division is a leading CBD cosmetic brand with distribution deals across a number of markets in which CBD-based products are permitted.
MGC Derma is a joint venture with widely recognised cosmetics manufacturer, Dr. M. Burstein Ltd., operating in Europe, of which MGC Pharmaceuticals owns 51 per cent and retains management control.
Roby Zomer, MXC co-founder and CEO, said: “This agreement with a world-renowned beauty products e-tailer provides our Derma division with a new platform to market our growing range of CBD-based skin care products to a new and more diverse global cosmetics market.”
“Cult Beauty individually and carefully selects each product that is marketed through its site, so we are delighted that they have recognised the efficacy of our products which work with the body’s natural system to support the skin’s response,” Zomer continued.
MXC has been riding a considerable high so far this year, having officially launched its first Derma Plus product – the Herbal Relief Cream for relief of psoriasis – with two more to come in the near future.
MXC has also been one of several ASX pot-stocks to benefit from a recent legislative change that has significant implications for Australia’s nascent medical cannabis industry – the Australian government’s announcement at the beginning of January that it will allow the export of medical cannabis products.
This enables MXC to sharpen up its focus on a development plan for future Australian operations, with a clear federal legislative and regulatory framework now expected to be in place as of February.
The opening up of export opportunities for Australian producers means that in addition to supplying its Australian pharmaceutical pipeline, MXC will be able to expand into the sale of Australian manufactured medical cannabis products such as CannEpilTM, its adult epilepsy product.
CannEpil will be launched into the Australian market early this year. MXC has a supply agreement in place with specialist pharmaceutical wholesaler and distributor, HL Pharma – a deal that is set to generate considerable annual revenues for MXC.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
